Carisma Therapeutics, Inc.
CARM
$0.2153
$0.00180.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 31.59% | 41.13% | 57.95% | 22.99% | 51.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.59% | 41.13% | 57.95% | 22.99% | 51.71% |
| Cost of Revenue | -19.50% | -12.75% | 4.27% | 16.21% | 30.92% |
| Gross Profit | 32.37% | 25.99% | 8.37% | -14.62% | -26.55% |
| SG&A Expenses | -31.79% | 1.55% | 22.76% | 51.70% | 214.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.00% | -9.30% | 8.48% | 23.52% | 57.05% |
| Operating Income | 32.18% | 18.17% | 0.05% | -23.62% | -57.99% |
| Income Before Tax | 30.39% | 22.39% | 8.43% | -9.24% | -41.90% |
| Income Tax Expenses | -- | -200.00% | -200.00% | -200.00% | -- |
| Earnings from Continuing Operations | 30.39% | 22.82% | 8.90% | -8.93% | -41.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.39% | 22.82% | 8.90% | -8.93% | -41.90% |
| EBIT | 32.18% | 18.17% | 0.05% | -23.62% | -57.99% |
| EBITDA | 33.84% | 19.57% | 0.75% | -22.29% | -58.27% |
| EPS Basic | 57.94% | 85.26% | 90.31% | 92.01% | 87.89% |
| Normalized Basic EPS | 59.25% | 85.20% | 90.28% | 91.99% | 87.91% |
| EPS Diluted | 57.94% | 85.26% | 90.31% | 92.01% | 87.89% |
| Normalized Diluted EPS | 59.25% | 85.20% | 90.28% | 91.99% | 87.91% |
| Average Basic Shares Outstanding | 24.01% | 72.16% | 184.10% | 741.59% | 1,471.15% |
| Average Diluted Shares Outstanding | 24.01% | 72.16% | 184.10% | 741.59% | 1,471.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |